Developing the next generation of complement medicines
Complement Therapeutics GmbH (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.
Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.
The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
UK Atomic Energy Authority Research, National and local authorities | UK Atomic Energy Authority Research, National and local authorities | Other 12 May 2024 | | |
Gimv Financial Services | Gimv Financial Services | Other 30 Apr 2023 | | |
Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Other 30 Apr 2023 | |